Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial

Dr. Ostrominski discusses new data from ACC 2025 showing that finerenone improves outcomes in HFmrEF/HFpEF across all KDIGO kidney risk categories.

ReachMD Healthcare Image
Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

NEW FEATURES:

Register

We're glad to see you're enjoying Global Cardiology Academy…
but how about a more personalized experience?

Register for free